Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

173.70GBp
5:07pm IST
Change (% chg)

-4.80p (-2.69%)
Prev Close
178.50p
Open
177.00p
Day's High
178.60p
Day's Low
172.90p
Volume
396,876
Avg. Vol
510,694
52-wk High
200.10p
52-wk Low
140.00p

VEC.L

Chart for VEC.L

About

Vectura Group plc is a product development company. The Company focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). The Company has eight products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to... (more)

Overall

Beta: 0.38
Market Cap(Mil.): £732.80
Shares Outstanding(Mil.): 410.53
Dividend: --
Yield (%): --

Financials

  VEC.L Industry Sector
P/E (TTM): 114.50 31.82 38.73
EPS (TTM): 0.02 -- --
ROI: 2.70 15.16 14.47
ROE: 3.04 15.92 15.40
Search Stocks

BRIEF-Vectura completes clinical trial for asthama therapy

* Is eligible to receive a further $23 mln upon achievement of future pre-determined development milestones on VR315 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

08 Jan 2016

BRIEF-Vectura says to receive milestone payment of $3.75 mln

* Commencement of first phase III trial of inhaled triple therapy QVM149 for asthma and milestone payment

09 Dec 2015

BRIEF-Vectura posts smaller half-year pretax loss

* Half year pretax loss 5 mln stg vs 6.2 mln stg loss year ago

17 Nov 2015

BRIEF-Vectura announces development milestone with VR632 in the EU

* US FDA approves new dual combination bronchodilator Utibron Neohaler and stand-alone monotherapy Seebri Neohaler for patients with chronic obstructive pulmonary disease

30 Oct 2015

Earnings vs. Estimates

Search Stocks